ESMO 2014 press release: PIK3CA mutations blunt benefit of anti-HER2 drugs

Patients with HER2 positive breast cancer derive less benefit from anti-HER2 drugs when they have PIK3CA mutations, according to Dr Evandro de Azambuja, medical director of the Br.E.A.S.T. Data Centre, Jules Bordet Institute in Brussels, Belgium. de Azambuja commented on the impact of PIK3CA mutations as new data in the neoadjuvant setting was presented at the ESMO 2014 Congress in Madrid, Spain. Read more here.